Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia. It will describe who receives KarXT, how it is used in real-world practice, and how often healthcare services such as hospital visits are used. It will also explore information recorded by clinicians about schizophrenia symptoms

NCT Number	NCT07571148
Lead Sponsor	Bristol-Myers Squibb
Conditions	Schizophrenia
Enrollment	6,876 participants
Start Date	2026-01-16
Primary Completion	2026-03-25 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-06